{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:58:22Z","timestamp":1787623102286,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3602900"],"award-info":[{"award-number":["2022YFC3602900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Aging"],"DOI":"10.1038\/s41514-026-00387-5","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:54:20Z","timestamp":1776495260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Global stagnation and misaligned priorities in BPH drug development: a 25-year landscape analysis of clinical trial registries"],"prefix":"10.1038","volume":"12","author":[{"given":"Zexuan","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"387_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajur.2017.06.004","volume":"4","author":"KB Lim","year":"2017","unstructured":"Lim, K. B. Epidemiology of clinical benign prostatic hyperplasia. Asian J. Urol. 4, 148\u2013151 (2017).","journal-title":"Asian J. Urol."},{"key":"387_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/pros.24656","volume":"84","author":"D Cavanaugh","year":"2024","unstructured":"Cavanaugh, D. et al. Link between circadian rhythm and benign prostatic hyperplasia (BPH)\/lower urinary tract symptoms (LUTS). Prostate. 84, 417\u2013425 (2024).","journal-title":"Prostate."},{"key":"387_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90229-3","volume":"15","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Comprehensive analysis of the global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021. Sci Rep. 15, 5644 (2025).","journal-title":"Sci Rep."},{"key":"387_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pop.2019.02.003","volume":"46","author":"RC Langan","year":"2019","unstructured":"Langan, R. C. Benign prostatic hyperplasia. Prim Care. 46, 223\u2013232 (2019).","journal-title":"Prim Care."},{"key":"387_CR5","first-page":"235","volume":"47","author":"RJ Simpson","year":"1997","unstructured":"Simpson, R. J. Benign prostatic hyperplasia. Br. J. Gen. Pract. 47, 235\u2013240 (1997).","journal-title":"Br. J. Gen. Pract."},{"key":"387_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-med-063014-123902","volume":"67","author":"EH Kim","year":"2016","unstructured":"Kim, E. H., Larson, J. A. & Andriole, G. L. Management of benign prostatic hyperplasia. Annu. Rev. Med. 67, 137\u2013151 (2016).","journal-title":"Annu. Rev. Med."},{"key":"387_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/path.5859","volume":"256","author":"IV Zabbarova","year":"2022","unstructured":"Zabbarova, I. V. et al. Benign prostatic hyperplasia\/obstruction ameliorated using a soluble guanylate cyclase activator. J. Pathol. 256, 442\u2013454 (2022).","journal-title":"J. Pathol."},{"key":"387_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JU.0000000000003999","volume":"212","author":"D Staskin","year":"2024","unstructured":"Staskin, D. et al. Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial. J. Urol. 212, 256\u2013266 (2024).","journal-title":"J. Urol."},{"key":"387_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.7326\/M23-0113","volume":"176","author":"GW Smetana","year":"2023","unstructured":"Smetana, G. W., Smith, C. C., Singla, A. & Libman, H. How would you manage this patient with benign prostatic hyperplasia? : Grand rounds discussion from Beth Israel Deaconess Medical Center. Ann. Intern. Med. 176, 545\u2013555 (2023).","journal-title":"Ann. Intern. Med."},{"key":"387_CR10","first-page":"662","volume":"54","author":"CG Roehrborn","year":"1999","unstructured":"Roehrborn, C. G. et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urol. 54, 662\u2013669 (1999).","journal-title":"PLESS Study Group. Urol."},{"key":"387_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/jama.2025.7045","volume":"334","author":"JT Wei","year":"2025","unstructured":"Wei, J. T., Dauw, C. A. & Brodsky, C. N. Lower urinary tract symptoms in men: a review. JAMA. 334, 809\u2013821 (2025).","journal-title":"JAMA."},{"key":"387_CR12","doi-asserted-by":"publisher","first-page":"e2248135","DOI":"10.1001\/jamanetworkopen.2022.48135","volume":"5","author":"M Garcia-Argibay","year":"2022","unstructured":"Garcia-Argibay, M., Hiyoshi, A., Fall, K. & Montgomery, S. Association of 5\u03b1-reductase inhibitors with dementia, depression, and suicide. JAMA Netw. Open. 5, e2248135 (2022).","journal-title":"JAMA Netw. Open."},{"key":"387_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/acel.70180","volume":"24","author":"Z Li","year":"2025","unstructured":"Li, Z. et al. Single-cell sequencing reveals that CD4+ T cells eliminate senescent prostate epithelium to delay progression of benign prostatic hyperplasia. Aging Cell. 24, e70180 (2025).","journal-title":"Aging Cell."},{"key":"387_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07783-x","volume":"16","author":"J Li","year":"2025","unstructured":"Li, J. et al. TNF-\u03b1 modulates cell proliferation via SOX4\/TGF-\u03b2\/Smad signaling in benign prostatic hyperplasia. Cell Death Dis. 16, 472 (2025).","journal-title":"Cell Death Dis."},{"key":"387_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08027-8","volume":"16","author":"TT Liu","year":"2025","unstructured":"Liu, T. T. et al. ZC3H4, a novel regulator of mitochondrial complex I, impacts prostate stromal cell senescence, attachment, adhesion and anoikis resistance. Cell Death Dis. 16, 741 (2025).","journal-title":"Cell Death Dis."},{"key":"387_CR16","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/cells14080608","volume":"14","author":"S Alqahtani","year":"2025","unstructured":"Alqahtani, S. et al. SASP modulation for cellular rejuvenation and tissue homeostasis: therapeutic strategies and molecular insights. Cells. 14, 608 (2025).","journal-title":"Cells."},{"key":"387_CR17","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.3390\/cells11203324","volume":"11","author":"LY Chou","year":"2022","unstructured":"Chou, L. Y., Ho, C. T. & Hung, S. C. Paracrine senescence of mesenchymal stromal cells involves inflammatory cytokines and the NF-\u03baB Pathway. Cells. 11, 3324 (2022).","journal-title":"Cells."},{"key":"387_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01644-4","volume":"22","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Aberrant activation of TGF-\u03b2\/ROCK1 enhances stemness during prostatic stromal hyperplasia. Cell Commun. Signal. 22, 257 (2024).","journal-title":"Cell Commun. Signal."},{"key":"387_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s43556-024-00216-9","volume":"5","author":"S Shan","year":"2024","unstructured":"Shan, S. et al. Y-27632 targeting ROCK1&2 modulates cell growth, fibrosis and epithelial-mesenchymal transition in hyperplastic prostate by inhibiting \u03b2-catenin pathway. Mol. Biomed. 5, 52 (2024).","journal-title":"Mol. Biomed."},{"key":"387_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/d41573-021-00190-9","volume":"21","author":"DG Brown","year":"2022","unstructured":"Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A. & Southall, N. Clinical development times for innovative drugs. Nat. Rev. Drug Discov. 21, 793\u2013794 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"387_CR21","unstructured":"U.S. Food and Drug Administration. FDA Modernization Act of 1997, Section 113: Clinical trials database requirement. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK338089."},{"key":"387_CR22","unstructured":"U.S. Congress. FDA Amendments Act of 2007, Section 801: Expanded clinical trial registration and results reporting. Available from: https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-110publ85\/html\/PLAW-110publ85.htm."},{"key":"387_CR23","doi-asserted-by":"publisher","first-page":"k2130","DOI":"10.1136\/bmj.k2130","volume":"361","author":"M Zwierzyna","year":"2018","unstructured":"Zwierzyna, M., Davies, M., Hingorani, A. D. & Hunter, J. Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005. BMJ. 361, k2130 (2018).","journal-title":"BMJ."},{"key":"387_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1228148","volume":"14","author":"ED Namiot","year":"2023","unstructured":"Namiot, E. D. et al. The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs. Front Pharmacol. 14, 1228148 (2023).","journal-title":"Front Pharmacol."},{"key":"387_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1394803","volume":"11","author":"S Li","year":"2025","unstructured":"Li, S. et al. Re-analysis of the current status of clinical trial registration in China. Front. Med. 11, 1394803 (2025).","journal-title":"Front. Med."},{"key":"387_CR26","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.7150\/ijbs.85089","volume":"19","author":"T Cao","year":"2023","unstructured":"Cao, T. et al. Rapamycin and low-dose IL-2 mediate an immunosuppressive microenvironment to inhibit benign prostatic hyperplasia. Int. J. Biol. Sci. 19, 3441\u20133455 (2023).","journal-title":"Int. J. Biol. Sci."},{"key":"387_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29719-1","volume":"13","author":"RE Vickman","year":"2022","unstructured":"Vickman, R. E. et al. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease. Nat. Commun. 13, 2133 (2022).","journal-title":"Nat. Commun."},{"key":"387_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103511","volume":"23","author":"V Liedtke","year":"2024","unstructured":"Liedtke, V., St\u00f6ckle, M., Junker, K. & Roggenbuck, D. Benign prostatic hyperplasia - A novel autoimmune disease with a potential therapy consequence?. Autoimmun Rev. 23, 103511 (2024).","journal-title":"Autoimmun Rev."},{"key":"387_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1158\/2643-3230.BCD-21-0130","volume":"2","author":"SC Wei","year":"2021","unstructured":"Wei, S. C., Mancuso, J. J., Daver, N. & Allison, J. P. Checkpoint Blockade + Chemotherapy: the right combination for AML? Blood Cancer Discov. 2, 551\u2013554 (2021).","journal-title":"Blood Cancer Discov."},{"key":"387_CR30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/bph.15276","volume":"178","author":"R Manzano","year":"2021","unstructured":"Manzano, R. et al. What skeletal muscle has to say in amyotrophic lateral sclerosis: Implications for therapy. Br. J. Pharmacol. 178, 1279\u20131297 (2021).","journal-title":"Br. J. Pharmacol."},{"key":"387_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/path.5751","volume":"255","author":"DB Joseph","year":"2021","unstructured":"Joseph, D. B. et al. Single-cell analysis of mouse and human prostate reveals novel fibroblasts with specialized distribution and microenvironment interactions. J Pathol. 255, 141\u2013154 (2021).","journal-title":"J Pathol."},{"key":"387_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ajpath.2013.11.015","volume":"184","author":"P Vital","year":"2014","unstructured":"Vital, P., Castro, P., Tsang, S. & Ittmann, M. The senescence-associated secretory phenotype promotes benign prostatic hyperplasia. Am. J. Pathol. 184, 721\u2013731 (2014).","journal-title":"Am. J. Pathol."},{"key":"387_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1585446","volume":"16","author":"MM Broman","year":"2025","unstructured":"Broman, M. M. et al. Immune cell single-cell RNA sequencing analyses link an age-associated T cell subset to symptomatic benign prostatic hyperplasia. Front. Immunol. 16, 1585446 (2025).","journal-title":"Front. Immunol."},{"key":"387_CR34","doi-asserted-by":"publisher","first-page":"e109102","DOI":"10.1371\/journal.pone.0109102","volume":"9","author":"TM Bauman","year":"2014","unstructured":"Bauman, T. M. et al. Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules. PLoS ONE 9, e109102 (2014).","journal-title":"PLoS ONE"},{"key":"387_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10522-025-10226-x","volume":"26","author":"A Khan","year":"2025","unstructured":"Khan, A. et al. Exploring TGF-\u03b2 signaling in benign prostatic hyperplasia: from cellular senescence to fibrosis and therapeutic implications. Biogerontology. 26, 79 (2025).","journal-title":"Biogerontology."},{"key":"387_CR36","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.lfs.2012.09.017","volume":"91","author":"FK Delella","year":"2012","unstructured":"Delella, F. K., Lacorte, L. M., Almeida, F. L., Pai, M. D. & Felisbino, S. L. Fibrosis-related gene expression in the prostate is modulated by doxazosin treatment. Life Sci. 91, 1281\u20131287 (2012).","journal-title":"Life Sci."},{"key":"387_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41391-023-00731-w","volume":"27","author":"S Gravas","year":"2024","unstructured":"Gravas, S. et al. Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression. Prostate Cancer Prostatic Dis. 27, 469\u2013477 (2024).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"387_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15913-6","volume":"11","author":"D Liu","year":"2020","unstructured":"Liu, D. et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat. Commun. 11, 1987 (2020).","journal-title":"Nat. Commun."},{"key":"387_CR39","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.230555","volume":"309","author":"X Wu","year":"2023","unstructured":"Wu, X., Zhou, A., Heller, M., Chi, T. & Kohlbrenner, R. Comparison of minimally invasive procedures for benign prostatic hyperplasia: a cost-effectiveness analysis. Radiology. 309, e230555 (2023).","journal-title":"Radiology."},{"key":"387_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104590","volume":"206","author":"MS Hassan","year":"2025","unstructured":"Hassan, M. S. et al. Emerging therapeutic frontiers in prostate health: Novel molecular targets and classical pathways in comparison with BPH and prostate cancer. Crit. Rev. Oncol. Hematol. 206, 104590 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"387_CR41","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/path.5857","volume":"256","author":"DB Joseph","year":"2022","unstructured":"Joseph, D. B. et al. 5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia. J. Pathol. 256, 427\u2013441 (2022).","journal-title":"J. Pathol."},{"key":"387_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114047","volume":"204","author":"E Lenglin\u00e9","year":"2024","unstructured":"Lenglin\u00e9, E. et al. Composite event-free-survival as an endpoint in oncology drug evaluation: review and guidance perspectives from the Haute Autorit\u00e9 de Sant\u00e9 (HAS). Eur. J. Cancer. 204, 114047 (2024).","journal-title":"Eur. J. Cancer."},{"key":"387_CR43","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/jbmr\/zjae201","volume":"40","author":"M Schini","year":"2025","unstructured":"Schini, M. et al. The relationship between baseline bone mineral density and fracture incidence in the placebo groups of randomized controlled trials using individual patient data from the FNIH-ASBMR-SABRE project. J. Bone Miner. Res. 40, 307\u2013314 (2025).","journal-title":"J. Bone Miner. Res."}],"container-title":["npj Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00387-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:20:02Z","timestamp":1781742002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00387-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["387"],"URL":"https:\/\/doi.org\/10.1038\/s41514-026-00387-5","relation":{},"ISSN":["2731-6068"],"issn-type":[{"value":"2731-6068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}